Evidence for life-science deals.
Lattis is an agentic research desk for biopharma, biotech, medtech and life-science tools companies. We look for assets that fit your mandate, and for companies that could license or buy the ones you want to sell. Each finding cites dated sources; a person signs each brief.
Agents for your pipeline
Business development turns on two questions: what could we bring in, and who could license or buy what we want to sell? Lattis researches both.
AI agents gather and organize the public evidence for each brief. A person checks the result and signs it.
Buy side: assets to bring in
For search and evaluation, in-licensing and M&A teams.
- Your mandate, agreed before research starts: therapy or technology area, modality, stage and exclusions.
- Programs and technologies we find inside that mandate, with dated, linked evidence for each.
- Not claimed: that an asset can be licensed, that the list is exhaustive, or which one to pursue.
Sell side: potential buyers and licensees
For BD and out-licensing teams with an asset to license or sell.
- Your question, agreed before research starts: the asset, rights already granted and companies to leave out.
- Companies whose public activity suggests a fit, with dated, linked evidence for each. Why a company is listed is labeled as inference.
- Not claimed: that the list is exhaustive, that a company wants the asset, or what it would pay.
How a brief works
Each finding cites its source and date and says whether it is established or inference. Where a brief orders candidates, the order follows weights you set and is stamped “Ranking not validated”. Briefs arrive as a PDF by email.
What the evidence covers
Briefs quote dated public sources: US granted patents, SEC filings, ClinicalTrials.gov records, company pipeline pages and press releases. The patent corpus holds US granted patents in bio/pharma and medtech from 2006 onward: 885,069 patents as counted on September 24, 2026. Its coverage of life-science tools has not been measured.
Coverage is US-centric. A program that appears in none of these sources will be missed, and US patents say nothing about protection elsewhere. Lattis does not establish who owns a patent today, its assignment history, its legal or maintenance-fee status, or freedom to operate.
Rules we work by
- We never act for both sides of the same transaction.
- By policy, what a client or prospect tells us in confidence never informs another client’s work.
- We do not value assets, advise on deal terms or make introductions.
- Research, not legal advice, and not a recommendation to transact.
Who we are
Looking for assets to bring in, or potential buyers for yours? Request a brief.